SCHEMBL622333

SCHEMBL622333

O=C(CBr)Cc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.52
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
CTBP2 P56545 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
PIK3CA P42336 2/20 0.46
MAPT P10636 2/20 0.46
CNR2 P34972 1/20 0.46
CYP3A4 P08684 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5595315 0.89 LTA4H (0.50) GSK3BKMT2ACNR2CYP3A4ALDH1A1
SCHEMBL1479915 0.86 NPC1 (0.55) NPC1RAB9ACTBP2MEN1KMT2A
SCHEMBL12731514 0.83 NPC1 (0.46) GSK3BNPC1RAB9ACTBP2MEN1
SCHEMBL5042101 0.80 GSK3B (0.50) GSK3BNPC1RAB9AMEN1KMT2A
SCHEMBL6238483 0.80 CA2 (0.58) NPC1RAB9ACTBP2MEN1KMT2A
SCHEMBL2251562 0.80 RAB9A (0.50) GSK3BNPC1RAB9ACTBP2MEN1
SCHEMBL4632976 0.80 NPC1 (0.50) NPC1RAB9ACTBP2MEN1KMT2A
SCHEMBL2547138 0.79 PLAAT3 (0.49) GSK3BMEN1KMT2A
SCHEMBL756910 0.78 PTPN1 (0.52) RAB9ACTBP2KMT2ALMNAHTT
SCHEMBL14149286 0.78 CPA1 (0.38) LMNAHTTL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-7011195-A None JP disclosed
WO-2016006593-A1 NOVEL BENZOXAZINE DERIVATIVE AND MEDICINE COMPRISING SAME 国立研究開発法人国立長寿医療研究センター 2016-01-14 WO disclosed
US-20150175563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175563-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175593-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175593-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-20150175593-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-06-25 US disclosed
US-8796271-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-8796271-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
WO-2012021696-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
WO-2012021696-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
WO-2011038293-A1 CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-03-31 WO disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
JP-H0711195-A WAX TAJIMA INC 1995-01-13 JP disclosed
US-4831047-A Tetrazolyl compounds and insecticidal use thereof IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-05-16 US disclosed
EP-0181687-A2 Tetrazolyl compounds useful as insectides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-05-21 EP disclosed
WO-1986002072-A1 TETRAZOLYL COMPOUNDS USEFUL AS INSECTICIDES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175563-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 GSK3B 57/4885NPC1 2007/4885RAB9A 1392/4885
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A GSK3B 995/4885NPC1 867/4885RAB9A 2286/4885
US-20150175593-A1 HETEROARYLS AND USES THEREOF PIK3R1, PIK3R2, PIK3R3 GSK3B 42/4885NPC1 1490/4885RAB9A 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.